Home > Dermatology > AAD 2022 > New Developments and Unmet Needs in Dermatology > New anticholinergic preparation is effective and tolerable in hyperhidrosis

New anticholinergic preparation is effective and tolerable in hyperhidrosis

Presented By
Prof. David Pariser, Eastern Virginia Medical School, USA
Presented by
David Pariser
Conference
AAD 2022
Trial
Phase 3, Cardigan I and II
Topically applied sofpironium bromide gel proved to be effective and well tolerated in the phase 3 Cardigan I and Cardigan II trials for patients with primary axillary hyperhidrosis. Both subjective and objective parameters were improved with only mild anticholinergic side effects due to its rapid metabolism. Of patients suffering from hyperhidrosis, 75% report a profoundly negative impact on their social life, well-being, and emotional and mental health [1]. Long-term treatment is often necessary given the chronic nature of primary axillary hyperhidrosis. Sofpironium is an analogue of the anticholinergic agent glycopyrrolate. In contrast to the latter, sofpironium is a retro-metabolic molecule, which is designed to undergo rapid metabolism into less active moieties following absorption after topical application. Due to this short systemic half-life, better tolerability can be expected. The identically designed Cardigan I (


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on